Vaccination against infectious disease following hematopoietic stem cell transplantation  by Avigan, David et al.
171B B & M T
INTRODUCTION
Patients who undergo myeloablative therapy followed
by hematopoietic stem cell transplantation (HSCT) for
the treatment of malignancy experience a prolonged
period of dysfunctional immunity that persists for up to
1 year or longer [1-5]. During this period, patients are at
increased risk for the development of infections repre-
senting a major source of morbidity and mortality [6-13].
Treatment of infections in this patient population is com-
promised by poor host immunity and the presence of
resistant organisms due to exposure to multiple cycles of
antibiotics.
One approach to limiting the risk of infection in
patients after HSCT is the use of vaccines that target com-
mon bacterial and viral pathogens. However, the efﬁcacy of
immunization in this patient population is limited signifi-
cantly by previous exposure to cytotoxic agents and the
dysfunctional immunity that characterizes the posttrans-
plantation period [14,15]. Furthermore, vaccine responses
are signiﬁcantly reduced in the early posttransplantation set-
ting, which often represents the period of highest risk for
infection. As a result, universally accepted guidelines for
vaccination of patients following HSCT have not been
established. Recently published surveys in Europe and the
United States indicate that there is considerable variability
in the practice guidelines of transplantation centers with
respect to the vaccination of patients after transplantation
[16]. Centers participating in the National Marrow Donor
Program report that vaccination for inﬂuenza, Streptococcus
pneumoniae, or tetanus was documented in 50% to 90% of
patients [17]. Vaccine efﬁcacy in this patient population has
not been studied in large multicenter trials.
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ABSTRACT
Patients undergoing hematopoietic stem cell transplantation (HSCT) experience a prolonged period of dysfunc-
tional immunity associated with an increased risk of bacterial and viral infections. Effective approaches toward vacci-
nating patients against common pathogens are being explored but are limited by poor levels of responsiveness. Rel-
evant studies examining the nature of reconstitution of cellular and humoral immunity and its impact on vaccination
strategies against infectious pathogens are reviewed. Following transplantation, deficiencies in cellular immunity are
characterized by the inversion of CD4/CD8 ratios, a decreased proliferative response to mitogens, and the develop-
ment of anergy to recall antigens as measured by delayed-type hypersensitivity testing. The impact on humoral
immunity consists of decreased levels of circulating immunoglobulin, impaired immunoglobulin class switching, and
a loss of complexity in immunoglobulin gene rearrangement patterns. In this setting, a loss of protective immunity
has been demonstrated against viral and bacterial pathogens previously targeted by childhood vaccination. Infec-
tions due to encapsulated bacterial organisms such as Streptococcus pneumoniae and Haemophilus influenzae type B
remain prevalent even in the late posttransplantation period. The efficacy of vaccination following HSCT is influ-
enced by the time elapsed since transplantation, the nature of the hematopoietic graft, the use of serial immuniza-
tion, and the presence of graft-versus-host disease. Strategies to enhance vaccine efficacy include pretransplantation
immunization of the stem cell donor and the use of cytokine adjuvants.
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RECONSTITUTION OF IMMUNITY FOLLOWING HSCT
After exposure to high-dose cytotoxic therapy, recov-
ery of cellular and humoral immunity is predominantly
dependent on the reconstitution of lymphoid elements
(Table). The nature of posttransplantation dysfunctional
immunity arises from quantitative and qualitative abnor-
malities in B- and T-cell populations which, in the
absence of chronic graft-versus-host disease (cGVHD),
largely resolves in 6 to 12 months [1-5]. In adult recipi-
ents of allogeneic bone marrow transplants, reconstitution
of immunity is particularly delayed because reeducation of
donor lymphoid cells occurs in a foreign environment in
the absence of a functional thymus. This defect is further
exacerbated by the use of immunosuppressive agents
required as prophylaxis for GVHD. Recovery of immunity
is more rapid in patients who receive peripheral blood
stem cells (PBSC) compared with patients who receive
bone marrow, and is delayed in recipients of T-
cell–depleted allografts [18-21].
Reconstitution of Cellular Immunity
The number of circulating CD3+ T cells recovers
shortly after transplantation, however, patients experience
prolonged inversion of the CD4/CD8 ratio due to the rela-
tive absence of CD4+ helper cells and the increased presence
of CD8+ suppressor cells [22-27]. In addition, there is a deﬁ-
ciency in the number of naive CD45RA+ T cells generated
during this period. This abnormality is most profound for
the CD4+/CD45RA+ subset, which may not recover for up
to 2 years posttransplantation. The posttransplantation
period is characterized by a loss of T cell–receptor diversity
which persists for greater than 1 year [28,29]. As seen in
fetal development, there is a relative increase in the
proportion of T cells expressing the γ/δ receptor as well as a
predominance of particular variable γ/δ and α/β gene
rearrangement patterns. T cells bearing the γ/δ receptor
express a limited portion of the variable region, are inca-
pable of MHC-restricted recognition of antigens and may
be cytolytic against CD4+ and CD8+ T cells expressing the
α/β receptor [30,31]. Therefore, the posttransplantation
phenotype of the T-cell receptor results in signiﬁcant limi-
tations in the repertoire of cellular immunity.
In vitro assays of T-cell function remain abnormal for
approximately 6 to 12 months following transplantation [32-
35]. Proliferative responses to anti-CD3 antibodies, inter-
leukin (IL)-2, and allogeneic lymphocytes are significantly
blunted. T-cell production of IL-2 in response to stimulation
with mitogens or alloantigens is markedly diminished [34].
Delayed-type hypersensitivity reactions to recall antigens are
largely absent and recover only in the absence of cGVHD.
Cytolytic activity of CD8+ lymphocytes is compromised after
allogeneic transplantation, as seen in the ineffective
responses mounted against Epstein-Barr virus [36].
In contrast, reconstitution of natural killer (NK) cells
does not require a functional thymus and occurs rapidly in
the posttransplantation period [1]. The number of circulat-
ing CD3–CD16+CD56+ cells are increased in the ﬁrst month
after allogeneic and autologous transplantation and remain
at normal to increased levels throughout the ﬁrst 3 months
[23]. In vitro killing of the NK-sensitive cell line, K562, by
IL-2–stimulated NK cells returns to normal levels within
4 to 6 weeks following transplantation.
With regard to risk of infectious complications follow-
ing HSCT, the importance of cellular reconstitution of
immunity is exemplified by the role of cytomegalovirus
(CMV) immunity in the posttransplantation patient. In
1 study of 47 patients who underwent allogeneic bone
marrow transplantation, between day 30 and day 40 post-
transplantation, a minority of patients demonstrated evi-
dence of CMV-specific T-cell immunity [37]. Recovery
Impact of Hematopoietic Stem Cell Transplantation on Cellular and Humoral Immunity*
B cells T cells NK cells
Phenotype BM B cells express increased CD10 for 1 year [24]. Inversion of CD4/CD8 for Recovery of
Decreased numbers of circulating CD19 and 6-12 months [23-28]. CD3–/CD16+/CD56+ cells
CD20 cells for 3-6 months [24,56-59]. Decreased CD45RA+, most to normal or increased
Immature phenotype of circulating B cells—CD23+, prominantly CD4+/CD45RA+ levels in the immediate
CD38+, IgM+— for 1 year [24]. Loss of complexity [23-28]. posttransplantation
of Ig gene rearrangement with loss of VH3 and Loss of T-cell receptor period [24].
increased VH2, VH4, VH5, and VH6 gene diversity [29-30]. 
families [64-69].
In vitro assessment Decreased proliferative response to Staphylococcus Decreased proliferative response
of function aureus, Cowan strain I and pokeweed mitogen to anti-CD3, IL-2, and alloMLR
for 3 months [60]. [33-36].
Decreased IgM production in response to novel Decreased CTL response against
and recall antigens for 6 months [63]. EBV [37].
Decreased IL-2 production.
In vivo assessment Decreased IgM, IgG, and IgA levels for 3 months, Loss of DTH response to recall
of function 6-9 months, and >2 years, respectively. antigens [1-3].
Blunted secondary responses in setting of 
cGVHD [1-3,61-64].
*BM indicates bone marrow; IL, interleukin; alloMLR, allogeneic mixed lymphocyte reactions; CTL, cytotoxic T lymphocyte; EBV, Epstein-
Barr virus; DTH, delayed-type hypersensitivity; cGVHD, chronic graft-versus-host disease.
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typically occurred between 40 and 90 days and was more
rapid in those receiving bone marrow from seropositive
donors. The presence of CMV-specific cytotoxic T lym-
phocytes (CTL) was protective against the development of
CMV disease. In contrast, CMV-specific immunity is more
rapidly reconstituted following autologous transplanta-
tion [38]. In the first 3 months posttransplantation, CMV-
reactive CD8+ and CD4+ populations have been demon-
strated in 80% and 93% of patients, respectively, and was
associated with protection from CMV infection. Immun-
odominant peptides such as pp65 have been identified that
are targets for CMV-specific CTL and their presence has
been confirmed by the use of tetramer technology [39,40].
Several studies have documented increased risk of CMV
infection in patients undergoing T-cell–depleted trans-
plantation which is associated with more delayed recovery
of CTL-specific immunity [41-44]. Late infection with
CMV correlated with an absence of in vitro T-cell prolif-
erative response to CMV at day 120 posttransplantation
[45]. Lack of CMV-specific T-cell responses have also cor-
related with the progression of CMV viremia to pneu-
monitis [46].
Infusion of unmanipulated donor lymphocytes has been
associated with more rapid T-cell reconstitution and resolu-
tion of CMV infection [42]. Walter et al. [47] demonstrated
that infusion of CMV-speciﬁc CTL clones resulted in the
reconstitution of cellular immunity against CMV that per-
sisted for at least 12 weeks. Persistence of CMV immunity
was dependent on the presence of T-helper responses. CMV
viremia and CMV disease were not seen in the treated pop-
ulation. In another study [48], infusion of CMV-specific
CD8+ cells prevented CMV disease and was associated with
accelerated resolution of active infection. However, infusion
of the CMV-speciﬁc CTL did not result in complete clear-
ance of the latent CMV viral burden. 
Reconstitution of Humoral Immunity
B cells differentiate from hematopoietic stem cells resid-
ing in the bone marrow and complete their maturation
process in peripheral lymphoid tissue, often mediated by
antigen exposure. Immunoglobulin expression evolves with
B-cell maturation [49-51]. Heavy chain rearrangement and
cytoplasmic expression of the µ heavy chain is found in pre-
B cells and is followed by further heavy and light chain
rearrangements, expression of membrane-bound IgM and
IgD, and ﬁnally with production of high-afﬁnity IgG by the
mature B cell and plasma cell. Maturation of B cells can also
be traced by the expression of cell surface markers that are
characteristic of specific stages of differentiation [52-54].
CD10 is an early marker expressed by primitive B-cell pre-
cursor populations. CD19 expression is ﬁrst found in pre-B
cells and is signiﬁcantly augmented with maturation. Com-
pared to CD19, CD20 is first found at a somewhat later
stage of development and is lost upon differentiation into
plasma cells. CD38 is expressed early in B-cell development,
prior to heavy chain rearrangement, and is then found on
the cell surface of mature plasma cells. CD5+ B cells are
thought to represent primitive precursor B-cells that are the
predominant population in the fetus, but are found in less
than 5% to 10% of peripheral B cells in adults and are typi-
cally associated with expression of IgM or IgD.
The phenotypic and functional characteristics of post-
transplantation B-cell recovery mimic that seen early in
B-cell ontogeny [23,55-58]. In the immediate posttransplan-
tation period, increased numbers of bone marrow B cells
express the early precursor antigen CD10. During the ﬁrst
year after transplant, a majority of B cells in the peripheral
blood initially express CD1c, CD5, CD23 and CD38 as well
as membrane-bound IgM and IgD in a similar pattern to
that found in umbilical cord blood and neonates. In the
absence of GVHD, mature B-cell populations in the periph-
eral blood expressing CD19 and CD20 return to normal
levels after 3 to 6 months following autologous and allo-
geneic marrow transplantation [55]. Reconstitution is more
rapid in patients receiving autologous peripheral blood stem
cells and correlates with the presence of increased numbers
of mature, memory CD4+CD45RO+ helper T cells [23].
In vitro proliferative responses to B-cell mitogens are
blunted during the first several months posttransplanta-
tion [59]. Normal concentrations of serum IgM are seen 3 to
6 months after transplantation, but circulating IgG concen-
trations remain depressed for at least 9 months and IgA lev-
els may not recover for 2 years [1-3,60]. Recovery of IgG2
and IgG4 is particularly delayed [60,61]. A lack of T-cell
help in coordinating B-cell responses is thought to result in
impairment in immunoglobulin class switching. In the ﬁrst
3 months after transplantation, patients fail to mount a pri-
mary IgM response following immunization with novel anti-
gens such as keyhole limpet hemocyanin or phage φX174
[62]. In patients with cGVHD, this abnormality persists and
there is an inability to generate secondary IgG responses to
a subsequent rechallenge with the antigen.
Studies of immunoglobulin gene rearrangement in the
posttransplantation patient have yielded conﬂicting results as
to whether there is a loss of complexity similar to that found
in early ontogeny [63-68]. Normal B cell development is
characterized by increasing complexity of the immunoglobu-
lin loci due to the combinatorial diversity generated by
rearrangements of variable (V), diversity (D), and joining (J)
gene segments, the enzymatic insertion of non-germline
nucleotides and somatic hypermutation. In fetal development,
the VH6 gene, a variable gene family with a single locus and
the shortest D and J segments are most commonly used as a
part of germline gene rearrangement limiting the diversity of
the immunoglobulin repertoire. With maturation, there is a
repertoire shift characterized by the expanded use of the
large and complex VH3 family. Following transplantation,
preferred usage of VH6 gene segment has been reported.
Decreased rates of somatic mutation have been observed
90 days posttransplantation in recipients of allogeneic grafts.
IMPACT OF PERIPHERAL BLOOD STEM CELLS VERSUS
BONE MARROW ON POSTTRANSPLANTATION IMMUNITY
Recent studies suggest that reconstitution of cellular and
humoral immunity occurs more rapidly in recipients of
peripheral blood stem cell transplants compared with recipi-
ents of bone marrow [18-21]. Ottinger et al. [18] described
the nature of reconstitution of immunity in 40 allograft recip-
ients, 20 of whom received peripheral blood stem cells, and
compared this group with 20 patients who received bone
marrow. Recipients of peripheral blood stem cells consistently
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demonstrated higher levels of CD4+ and CD19+ cells and
increased proliferative responses to tetanus toxoid, Candida,
and T-cell mitogens. Talmadge et al. [19] demonstrated that
lymphoma patients who received transplants of peripheral
blood stem cells had higher CD4/CD8 ratios, NK cell activ-
ity, and proliferative and T-cell helper responses to mitogens
than patients who received bone marrow transplants. Given
the more rapid immunologic recovery in patients undergoing
peripheral blood stem cell transplantation, posttransplanta-
tion vaccination may be more efﬁcacious in these patients.
PATTERNS OF INFECTIONS IN THE
POSTTRANSPLANTATION PERIOD
The spectrum of infections observed after HSCT
reflects the nature of reconstitution of immunity in this
patient population (Figure 1) [69-72]. In the immediate
posttransplantation period, the presence of neutropenia, the
use of indwelling central venous catheters, and a damaged
gastrointestinal mucosal barrier commonly result in bacter-
ial infections due to gram-positive and enteric gram-negative
organisms. Superinfection with fungal organisms may sub-
sequently emerge in the setting of prolonged use of broad-
spectrum antibiotic therapy [73]. Reactivation of herpes
viruses is commonly observed in this period. After hemato-
poietic engraftment, patients remain at increased risk of
infection from bacterial, viral, and fungal pathogens, includ-
ing CMV, respiratory syncytial virus (RSV), inﬂuenza, and
Aspergillus, which contribute considerably to morbidity and
mortality [74-77]. Primary infection and reactivation of
varicella-zoster (VZV) occurs commonly after transplanta-
tion [78-81]. In 1 study, 216 of 1186 posttransplantation
patients developed VZV infection with dermatomal zoster,
representing 62% of infections and 32% of patients who
developed signs of disseminated disease [81]. Similar inci-
dences of posttransplantation VZV infection were seen in
both recipients of autologous and allogeneic transplants.
Risk factors for infection included patient age, (older than
10 years), prior TBI, and prior VZV seropositivity.
Bacterial infections are a signiﬁcant cause of morbidity
and mortality in patients in the late posttransplantation
period, particularly in patients undergoing allogeneic trans-
plantation and those with cGVHD [6,14,69-71]. Increased
rates of infection due to Streptococcus pneumoniae and
Haemophilus inﬂuenzae type B (Hib) have been documented in
these patients. Risk has been associated with low serum con-
centrations of IgG2 and IgG4 that persist for 1 year or longer
after transplantation [9,19,82,83]. Winston and coworkers
[83] documented 8 episodes of pneumococcal infection in 7
of 26 patients who survived more than 7 months posttrans-
plantation. Pneumococcal bacteremia occurred in 6 of 8 cases,
and was fatal in 2 patients. There was a strong correlation
between the development of pneumococcal infection and
depression of circulating levels of serum IgG and IgM, type-
Figure 1. Patterns of infection following hematopoietic stem cell transplantation showing the usual approximate time to onset of major complica-
tions. Adapted with permission from Chan CK, Hyland RH, Hutcheon MA. Pulmonary complications following bone marrow transplantation. Clin
Chest Med. 1990;11:323 and Krowk MJ, Rosenow EC. Pulmonary complications of bone marrow transplantation. Chest. 1985;87:237.
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speciﬁc antibody levels, and antibody-mediated opsonic activ-
ity. In one report, 6 cases of fatal pneumococcal sepsis were
documented, which represented 2% of the patient population
that had survived more than 3 months following transplanta-
tion [84]. Of note, 5 of 6 patients had evidence of cGVHD
and developed pneumococcal infections despite the use of
antibiotic prophylaxis. Another study examined the risk of
pneumococcal sepsis in 1277 patients with hematologic
malignancies who had undergone autologous, allogeneic, or
syngeneic transplantation from 1980 to 1997; the overall inci-
dence was 4% at 3 years, 5% at 7 years, and 8% at 12 years
posttransplantation [85]. The risk was increased in patients
who had received allogeneic grafts, total body irradiation, and
in those affected with cGVHD. Despite therapy, the mortal-
ity rate among infected patients was 23%. Hence, pneumo-
coccal infection remains a significant concern in the post-
transplantation patient and increased efforts to limit the risk
of disease are urgently needed.
VACCINATION STRATEGIES IN THE
IMMUNOCOMPROMISED HOST
A variety of factors complicate efforts to develop an effec-
tive vaccination strategy for patients following HSCT. Live,
attenuated viral vaccines are more potent in eliciting protective
responses than inactivated or killed vaccines, but the use of live
vaccines in immunocompromised patients is limited by con-
cerns regarding the risk of disseminated infection [15].
Responses to viral protein subunits are muted in cancer
patients, and booster injections are ineffective in patients
treated with cyclosporine [86,87]. Vaccination against the poly-
saccharide antigens of encapsulated organisms pose a particular
challenge in this patient population. Responses are B-cell
dependent, primarily restricted to the IgG2 subclass, and are
ampliﬁed by T-helper cell modulation [88,89]. The relative
absence of these aspects of host immunity in the posttransplan-
tation period result in ineffective responses to vaccination.
PosttransplantationVaccination Against Haemophilus
influenzae Type B
Vaccination against Hib was initially performed using the
polyribosyl phosphate polysaccharide capsular antigen but was
found to be minimally immunogenic in young children and
infants who were at the greatest risk for infection [90]. It was
subsequently discovered that the conjugation of the polysac-
charide with tetanus toxoid, diphtheria toxoid, CRM 157, and
the outer membrane protein of Neissseria meningitidis signiﬁ-
cantly augmented the immunogenicity of the vaccine. Sero-
logic antibody concentrations estimated to provide long term
protection against Hib have been deﬁned as ≥ 1.0 µg/mL.
Loss of Hib antibody titers, increased risk of infection,
and poor responses to vaccination have been documented in
patients after hematopoietic cell transplantation, and have
been correlated with deficiencies in serum IgG2 and IgG4
levels [14,91]. In 1 study, of 40 posttransplantation patients,
only 3 maintained protective antibody levels to Hib [92].
The response to Hib capsular antigen vaccine improved with
the use of a tetanus toxoid conjugate, particularly in patients
with pronounced IgG2 deficiency, and 85% of patients
undergoing serial vaccination ultimately developed protec-
tive immunity. In another study, 47 patients were immunized
with a Hib-polysaccharide–diptheria toxoid conjugate vac-
cine at various times following allogeneic or autologous stem
cell transplantation. Compared with prevaccination titers, a
2-fold or greater increase was seen in IgG, IgM, and IgA lev-
els in 53%, 49%, and 23% of patients, respectively [93].
Given the importance of reconstitution of immunity in
determining response to vaccination in the posttransplanta-
tion patient, a variety of studies have sought to identify the
optimal timing of immunization. In 1 report, 45 patients
undergoing allogeneic transplantation were randomized to
receive a single dose of the Hib conjugate vaccine at 6 or
18 months, respectively, after transplantation [94]. At the
time of vaccination, 3 of 19 patients in the early vaccination
group and 8 of 22 patients in the late vaccination group had
protective levels of antibodies against Hib, deﬁned as a titer
of ≥1 µg/mL. Twelve of 20 patients in the early group and
12 of 18 patients in the late group developed protective con-
centrations following vaccination. Four-fold increases in
antibody titers were seen equally in both groups. 
Vance and associates [95] studied patients who had
received serial vaccinations with a Hib conjugate beginning
at different time points. Those who began receiving vaccina-
tion at 3 or 6 months posttransplantation achieved higher
titers at 12 to 24 months than those who began at 12 months
posttransplantation, but > 80% of both groups achieved
adequate responses after 24 months posttransplantation.
Guinan et al. [96] reported on 21 allogeneic and 14 autolo-
gous transplantation patients who were immunized using
Hib conjugate vaccine either at both 12 and 24 months, or
only at 24 months posttransplantation. A protective antibody
level (>1.0 ng/mL) was seen in 56% of patients treated with a
single dose and in 80% of patients treated with the 2 doses.
Those patients vaccinated at both 12 and 24 months demon-
strated a signiﬁcantly higher geometric mean antibody con-
centration than those who received the single dose (14.5 µg/mL
versus 1.43 µg/mL). The data suggest that effective responses
to Hib have been accomplished through the use of polysac-
charide-protein conjugate vaccines and may be augmented
by repeated vaccination beginning early in the posttransplan-
tation period. However, a number of issues remain regarding
the Hib vaccine, including the optimal preparation and the
precise timing of vaccination to ensure a stable response
beginning early in the posttransplantation period.
PosttransplantationVaccination Against Streptococcus
pneumoniae
Several generations of pneumococcal vaccines have been
developed in an effort to generate immunity against the
capsular polysaccharides of the different serotypes. These
vaccines include an 8-valent preparation, the 14-valent
preparation licensed in 1977, and its successor, the 23-valent
vaccine licensed in 1983 [15]. The efficacy of vaccination
with the 23-valent vaccine was determined to be 61% to 75%
in immunocompetent recipients [97,98]. Protection has not
been reliably demonstrated in patients with immunodeﬁcient
states who are at greatest risk for infection. An antibody
titer of 300 ng/mL (antibody nitrogen) had been considered
protective, but initial measurements of antibody response
were performed using a radioimmunoassay that did not
separate effective serotype-speciﬁc antibodies from contam-
inating cell wall polysaccharide antibodies that do not
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mediate disease protection [99,100]. More recent studies
have used an enzyme-linked immunosorbent assay that
allows for the removal of nonspeciﬁc antibodies by preab-
sorption with cell wall polysaccharides as well as the identi-
fication of serotype-specific antibodies. Determination of
serum opsonic activity has also been assessed as a measure
of vaccine potency [101-103]. The presence of serotype-
specific antibody has correlated with protection, and
responses have correlated with prevaccination levels of anti-
body, particularly of the IgG2 subclass.
Several studies have documented a loss of protective
serum antibody levels to Streptococcus pneumoniae in the post-
transplantation period and a lack of response to vaccination.
Giebenk et al. [104] noted a signiﬁcant decline in serum IgG
antibody titers to 2 common serotypes during the ﬁrst year
posttransplantation, and type-speciﬁc antibody responses to
vaccination were lower than those seen in healthy, matched
controls. Lortan and colleagues [105] demonstrated a
signiﬁcant decrement of median IgG, IgG1, and IgG2 anti-
pneumococcal antibody concentrations compared with pre-
transplantation titers in children being treated for genetic
disease. Another study demonstrated 2- to 12-fold lower
antibody titers compared with a cohort of healthy controls
[106]. Failure to generate protective immunity in response
to vaccination was thought to be due to low baseline levels
of serum immunoglobulin, particularly IgG2 [105,107].
Several studies have found that patients who have
undergone allogeneic transplantation failed to generate
signiﬁcant increases in type-speciﬁc IgG or IgA in response
to the pneumococcal polysaccharide vaccine [95,107]. In
contrast to Hib vaccination, 2 studies demonstrated no
improvement in antibody responses following immunization
with a pneumococcal capsular polysaccharide conjugate vac-
cine compared with an unconjugated preparation [96,108].
Vaccination in the early posttransplantation period, corti-
costeroid therapy, and male sex are factors associated with
poor responses. The presence of GVHD has been found to
be predictive of poor response in some studies. In 1 study,
12.8% of patients vaccinated in the ﬁrst 6 months posttrans-
plantation subsequently developed pneumococcal infections
[106]. In approximately half of these cases, patients were
infected with a serotype for which they had been vaccinated
and had failed to develop protective levels of antibody. In
another study, 35 transplantation patients were immunized
with the 23-valent polysaccharide vaccine, and antibody
titers directed against 6 pneumococcal serotypes were deter-
mined. Protective immunity directed against all 6 serotypes
was seen in only 19% of patients. Vaccination was least effec-
tive in generating responses directed against serotype 6A,
with only 28% of patients achieving a titer of > 300 ng/mL.
Multiple regression analysis demonstrated only older age to
be a factor in predicting response [96].
Poor responses to pneumococcal vaccination have been
reported even in the late posttransplantation period. In
1 study, patients undergoing a single immunization at
20 months posttransplantation did not exhibit improved
responses compared with those who were vaccinated at
8 months posttransplantation [94]. In contrast, Avanzini and
coworkers [109] studied 53 patients who were immunized
with the 23-valent pneumococcal vaccine 6 months or later
after allogeneic or autologous transplantation. Protective
titers were achieved in 20% to 30%, 50%, and 100% of those
patients vaccinated at 6 to 12 months, 1 to 2 years, and after
2 years, respectively. Guinan et al. [96] studied the impact of
repeated immunizations by examining antibody response in
patients vaccinated at 12 and 24 months posttransplantation
compared with those who received a single vaccination at
24 months. Higher levels of response directed against the
serotypes 1 and 3 were seen in the 2-dose group. However,
no difference was demonstrated against less immunogenic
serotypes and the percent of patients with mean pneumococ-
cal protective titers was similar in both groups. In summary,
the data suggest an absence of an effective vaccination strat-
egy that provides protection against pneumococcal infection
in the ﬁrst 2 years posttransplantation.
PosttransplantationVaccination Against Tetanus
The need for reimmunization against tetanus in the
posttransplantation period has been supported by several
studies that document the loss of tetanus-specific immu-
nity following transplantation. In 1 review of 48 patients
undergoing allogeneic transplantation, 51% of patients
were seronegative at 1 year and all patients who were not
revaccinated lost protective antibody titers by 2 years post-
transplantation [110]. In another study of 45 patients who
underwent allogeneic transplantation, 90% demonstrated
protective titers of > 0.1 HU/mL which had fallen to 70%
by 18 months posttransplantation [111]. Hammarstrom
et al. [112] studied tetanus immunity in 90 patients, of
whom 52 had received autologous bone marrow trans-
plants and 38 had received peripheral blood stem cell
transplants. Seropositivity rates, as measured by the differ-
ence between pretransplantation and 1-year posttransplan-
tation antibody levels, fell from 58% to 29% in the bone
marrow recipient group and from 66% to 47% in the
peripheral blood stem cell recipient group. There was no
spontaneous recovery in those who became seronegative.
Patients subsequently underwent serial vaccination and all
achieved protective levels 1 year following vaccination.
Response to vaccination with tetanus toxoid is altered in
the posttransplantation patient with prolonged time to
reach peak antibody levels. One study showed that 64% of
patients immunized with tetanus toxoid at 1 year post-
transplantation responded with adequate antibody levels,
but 1 year later, only 33% of patients had maintained these
titers [111]. All patients who were reimmunized at 2 years
posttransplantation developed sustained protective
responses. Guinan et al. [96] demonstrated that patients
who were vaccinated with tetanus toxoid at both 12 and
24 months exhibited higher anti-toxoid antibody concen-
trations compared with those patients who received a sin-
gle vaccination at 24 months. Similarly, Vance et al. [95]
reported higher levels of antibody in patients who began
receiving immunization at 3 months posttransplantation
than in those who began at 12 months. 
PosttransplantationVaccination Against Viral
Pathogens
Measles, Mumps, and Rubella. A majority of patients
retain protective immunity to measles, mumps, and rubella
following autologous transplantation. In 1 study, 12%,
18%, and 6% of patients evaluated at 1 year after transplan-
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tation demonstrated a loss of protective immunity to
measles, rubella, and mumps respectively. Of the 6 children
vaccinated with live, trivalent, attenuated measles, mumps,
and rubella vaccine 1 to 2 years posttransplantation, 2, 6,
and 4 patients developed protective immunity to measles,
rubella, and mumps, respectively [113]. Ljungman et al.
[114] studied 57 patients who had undergone allogeneic
transplantation. Among patients who were seropositive
prior to transplantation, 51%, 42%, and 76% of patients
had maintained antibody levels at 2 years to measles,
mumps, and rubella, respectively. The presence of GVHD
was not found to be predictive of loss of immunity. Twenty
seronegative patients underwent vaccination with the triva-
lent, live, attenuated vaccine and 77%, 64%, and 75%
responded with seroprotective titers of measles, mumps, and
rubella, respectively. In a follow-up report on 124 patients,
it was demonstrated that the probability of maintaining
antiviral immunity progressively fell with only 20%, 6%,
and 28% of patients immune at 7 years to measles, mumps,
and rubella respectively [115]. The only predictive factor
for the preservation of immunity was whether the patient
had been immunized pretransplantation. In another study
of 22 pediatric patients undergoing allogeneic transplanta-
tion, none of the patients were seropositive to measles,
mumps, or rubella prior to vaccination with the MMR II
[116]. Immunization resulted in 68% of patients achieving
protective levels of immunity to all 3 viruses.
Poliovirus. In a study examining the impact of allo-
geneic transplantation on immunity against poliovirus, 37 of
55 patients maintained protective levels of antibody to the
3 polio virus strains examined [117]. In 50% of patients, at
least a 4-fold decrease in antibody levels directed against the
3 strains of virus was demonstrated. A 4-fold increase in anti-
body titers was seen in response to a single immunization
with the trivalent, inactivated vaccine in 42%, 36%, and 21%
to poliovirus types 1, 2, and 3, respectively. Serial vaccination
subsequently improved the response rate to 50%. Engelhard
et al. [118] demonstrated a decrease in polio titers in 42 patients
following transplantation, with a uniform rise in titers fol-
lowing the ﬁrst dose of inactivated polio vaccine. In another
study, equivalent responses to vaccination were seen in
groups randomized to immunization beginning at 6 and
18 months, respectively [119]. Loss of protective titers
against polio has also been demonstrated following autolo-
gous transplantation [120]. In 1 study, 22 of 102 patients did
not have detectable serum antibodies to at least 1 type of
poliovirus 1 year following autologous transplantation. At
3 years posttransplantation, an additional 6 patients had
become seronegative. The percentage of patients responding
to vaccination improved with serial immunization.
Hepatitis B. The hepatitis B vaccine consists of a viral
protein preparation that historically was derived from the
plasma of infected patients, but is now generated through
recombinant techniques. The newer vaccine has proved to
be somewhat less immunogenic. Approximately 25% of
adults with cancer being treated with chemotherapy fail to
develop protective antibody concentrations in response to
the vaccination [87]. Of 48 patients immunized with hepati-
tis B vaccines either prior to or following autologous bone
marrow transplantation, only 19 patients responded with
low but stable levels of antibody [121].
Influenza. The impact of vaccination against inﬂuenza
virus was studied in 35 and 13 patients undergoing allo-
geneic and autologous hematopoietic cell transplantation,
respectively. Immunization in the ﬁrst 6 months posttrans-
plantation was ineffective, and the likelihood of seroconver-
sion correlated with the interval between transplantation
and vaccination [122]. The presence of GVHD was associ-
ated with poor responses to the H1N1 strain.
Varicella-zoster. Cell-mediated immunity against vari-
cella is commonly lost in the posttransplantation period. In
1 study, T-cell response to varicella was preserved in 4 of
16 patients in whom the patient and donor had been
immune prior to transplantation [123]. Immunity was not
detected in transplantation recipients in whom the donor or
patient did not demonstrate a VZV response pretransplan-
tation. Redman et al. [124] examined the impact of the
heat-inactivated varicella vaccine in 75 patients who had
undergone HSCT. At 4 months posttransplantation,
patients who received monthly vaccination demonstrated a
4-fold increase in their stimulation index compared with
that of unvaccinated patients. The incidence of viral reacti-
vation was equivalent between the 2 arms of the study, but
the severity of disease was signiﬁcantly reduced in the vac-
cinated cohort. Sauerbrei et al. [125] studied 15 children
who were immunized against varicella between 12 and
23 months posttransplantation. Eight of the 9 patients who
were seronegative seroconverted, and 6 patients maintained
their virus-speciﬁc IgG 2 years after vaccination.
IMPACT OF PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION VERSUS BONE MARROW
TRANSPLANTATION ON VACCINE RESPONSE
A relative preservation of antibody titers posttransplan-
tation and improved responses to vaccination have been
noted following peripheral blood stem cell transplantation.
In 1 study, 47% of posttransplantation patients who received
peripheral blood stem cell transplants maintained protective
antibody titers to tetanus compared with 29% of those who
received autologous bone marrow transplants [112]. Chan
et al. [126] examined the efﬁcacy of serial tetanus toxoid and
Hib vaccination in patients with lymphoma, 17 of whom
received autologous bone marrow transplants and 10 of
whom received peripheral blood stem cell transplants. At
24 months, the geometric mean of IgG concentrations was
approximately 10-fold higher in patients who received
peripheral blood stem cell transplants. Protective levels of
Hib antibody were reached earlier in peripheral blood stem
cell group. These data suggest that the efﬁcacy of vaccina-
tion in patients who undergo HSCT may be significantly
improved in patients receiving peripheral blood stem cells
compared to that in patients who receive bone marrow
transplants, and immunization strategies may need to be
altered in this group of patients.
IMPACT OF PRETRANSPLANTATION OF DONOR AND
PATIENT IMMUNIZATION
Prior clinical studies have suggested that the presence of
disease-speciﬁc antibody titers of the donor impacts the risk
and severity of infection in recipients of an allogeneic trans-
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plant [127-130]. One strategy to improve the efﬁcacy of post-
transplantation vaccination is to immunize the donor in an
attempt to generate immunity that could be passively trans-
ferred to the transplantation recipient. Kato et al. [131]
demonstrated a decrease in incidence of varicella-zoster infec-
tion in recipients of allogeneic transplants from donors who
had been immunized 2 to 4 weeks prior to hematopoietic
stem cell harvest. Patients who underwent allogeneic trans-
plantation following donor immunization against tetanus and
diphtheria toxoids demonstrated a rapid rise in antibody
titers. Patients were immunized between 64 and 154 days
posttransplantation and developed a secondary antibody
response derived from the previously stimulated donor B cells.
In 1 study, 32 patients who underwent allogeneic transplanta-
tion received bone marrow from donors immunized with a
Hib conjugate vaccine, tetanus toxoid, and a 23-valent pneu-
mococcal vaccine [132]. Patients subsequently underwent ser-
ial vaccination at 3, 6, 12, and 24 months posttransplantation.
Titers of Hib and tetanus toxoid antibodies were increased
signiﬁcantly at 3, 6, 12, and 24 months posttransplantation
compared with a cohort of patients whose donors had not
been immunized. In contrast, donor immunization did not
augment the response to pneumococcal vaccination. Similar
ﬁndings were noted in patients who underwent autologous
transplantation who had been immunized with Hib, tetanus,
and pneumococcal vaccines prior to stem cell collection and
serially thereafter in the posttransplantation period [133].
Signiﬁcantly higher levels of Hib and tetanus antibody titers
were seen at 3 months posttransplantation compared with a
cohort of control patients who had not undergone pretrans-
plantation vaccination. In contrast, there was no beneﬁt to
pretransplantation vaccination against pneumococcal capsular
polysaccharide antigens.
APPROACHES TO AUGMENT VACCINE EFFICACY
Several strategies have been pursued to improve the efﬁ-
cacy of vaccination, including the use of adjuvants and
cytokines that enhance the responses of cellular and humoral
immune systems [134,135]. Aluminum salts and mineral oil
(Freund’s adjuvant) have been shown to improve responses to
immunization. The mechanism of action has not been fully
elucidated, but is thought to arise from the induction of an
inﬂammatory reaction with resultant recruitment of antigen-
presenting cells (APC) and cytokine release, which enhances
both humoral and cellular responses.
The use of cytokine therapy concurrent with vaccina-
tion has also been explored in immunocompromised
patients to determine if it can augment antigen-specific
immune responses. Several cytokines such as IL-1, IL-2,
interferon (IFN)α, IL-12, IL-6, and tumor necrosis factor
(TNF)-α have been shown to impact humoral and cellular
immunity and to augment antigen responsiveness in animal
models [134,135]. The use of IFNα resulted in earlier
responses to the hepatitis B vaccine in patients undergoing
hemodialysis, and improved responses to a peptide malarial
vaccine in healthy volunteers. IL-2 has been associated with
improved rates of seroprotection in dialysis patients vacci-
nated against hepatitis B [136].
Granulocyte-macrophage colony–stimulating factor
(GM-CSF) has shown promise as an effective strategy to
enhance responsiveness in settings of compromised immu-
nity. GM-CSF promotes the migration of inflammatory
cells, exerts immunomodulatory effects due to induction of
secondary cytokines, and plays a vital role in the maturation
and function of APC [137]. GM-CSF induces the release of
IL-1, IL-6 and TNF-α, which promotes the expansion and
differentiation of T and B cells. Most importantly, GM-CSF
is vital for the development of potent APC known as den-
dritic cells (DC) [138,139]. GM-CSF has also been shown
to enhance the efﬁcacy of hepatitis B and inﬂuenza vaccines
in immunocompromised patients [140,141].
CONCLUSION
HSCT is associated with a period of immunologic dys-
function that persists for up to 1 year or longer. Infectious
complications due to bacterial and viral organisms are a
major source of morbidity and mortality in the early and late
posttransplantation periods. HSCT is often associated with
a loss or diminution of protective immunity against
pathogens targeted by childhood immunizations such as
tetanus, mumps, rubella, and polio. As a result, there has
been interest in vaccinating patients in the posttransplanta-
tion period to reduce the risk of infection. However, the
efficacy of immunization of these patients has been ham-
pered by incompetent immunity, particularly in the early
posttransplantation period. Approaches to enhance the efﬁ-
cacy of immunization through the use of vaccine adjuvants,
polysaccharide-protein conjugates, and pretransplantation
vaccination are being explored. Based on the published liter-
ature, the Centers for Disease Control, Infectious Disease
Society of America, and the American Society of Blood and
Marrow Transplantation have issued recommendations
regarding the immunization of patients following HSCT
(Figure 2) [142].
The relatively small numbers of patients studied and the
heterogeneous nature of the patient population and trans-
plantation strategies have limited prior studies assessing the
effectiveness of vaccination following HSCT. The source of
the hematopoietic graft, (autologous versus allogeneic, bone
marrow versus peripheral blood stem cells), the underlying
disease process, prior exposure to chemotherapy, and the
design of the pretransplantation preparative regimen all
impact the speed of recovery of immunity and responsiveness
to posttransplantation vaccination. The use of T-cell deple-
tion methods, the purging of the graft with positive or nega-
tive selection techniques, and antibody therapy directed
against B and T cells also effect reconstitution of immunity
and further complicate the assessment of vaccine efficacy.
Large, multicenter trials are crucial to fully examine these
issues and to develop an effective strategy for vaccination in
these patients.
A prominent area of active research in cancer therapy has
been the development of tumor vaccines designed to
enhance the immunogenicity of tumor antigens and resulting
in the generation of effective tumor-speciﬁc responses. Anti-
tumor vaccine use in the posttransplantation period is being
explored as a strategy to eliminate minimal residual disease
and increase rates of durable remission. The effective use of
this strategy in the posttransplantation setting is dependent
on a complete understanding of the immunologic milieu and
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the associated ability to respond to vaccination. The knowl-
edge obtained in exploring approaches for infectious disease
vaccination in this setting may therefore carry significant
implications for cancer therapy as well.
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